SCHEMBL17809581

SCHEMBL17809581

Cc1cc(-c2ccc3c(c2)CCCN3C)n[nH]1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
WDR5 P61964 1/20 0.50
NOTUM Q6P988 3/20 0.47
ALDH1A1 P00352 2/20 0.46
MEN1 O00255 1/20 0.46
GAA P10253 1/20 0.46
MAPT P10636 1/20 0.46
HPGD P15428 1/20 0.46
KMT2A Q03164 1/20 0.46
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.43
ALK Q9UM73 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP19A1 P11511 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
SYK P43405 1/20 0.37
PRMT5 O14744 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17806358 0.83 NOTUM (0.50) WDR5NOTUMALDH1A1MAPTHPGD
SCHEMBL19369023 0.83 NOTUM (0.50) WDR5NOTUMALDH1A1MEN1GAA
SCHEMBL17809559 0.80 WDR5 (0.51) WDR5NOTUMALDH1A1MEN1GAA
SCHEMBL17864441 0.78 NOTUM (0.50) WDR5NOTUMALDH1A1MEN1GAA
SCHEMBL17809776 0.76 WDR5 (0.53) WDR5NOTUMALDH1A1MEN1GAA
SCHEMBL17809619 0.76 WDR5 (0.60) WDR5NOTUMALDH1A1MEN1GAA
SCHEMBL17809564 0.75 WDR5 (0.49) WDR5NOTUMALDH1A1MEN1GAA
SCHEMBL17809770 0.74 WDR5 (0.51) WDR5NOTUMALDH1A1MEN1GAA
SCHEMBL17809554 0.73 WDR5 (0.50) WDR5NOTUMALDH1A1MEN1GAA
SCHEMBL17809574 0.73 ALDH1A1 (0.51) WDR5NOTUMALDH1A1MEN1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3224258-B1 4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[4,3-C]PYRIDIN-3-AMINE COMPOUNDS AS CBP AND/OR EP300 INHIBITORS GENENTECH INC (US) 2019-08-14 EP disclosed
US-20170333406-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2017-11-23 US disclosed
US-9763922-B2 Therapeutic compounds and uses thereof GENENTECH, INC. (US) 2017-09-19 US disclosed
US-20160158207-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2016-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170333406-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF EP300, HDAC1, HDAC10 WDR5 621/4885NOTUM 3529/4885ALDH1A1 1727/4885
US-20160158207-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF EP300, HDAC1, HDAC10 WDR5 621/4885NOTUM 3529/4885ALDH1A1 1727/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.